SCHEMBL13890899

SCHEMBL13890899

O=C(O)c1ccc(Br)cc1Nc1ccc(F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 9/20 0.59
AKR1C2 P52895 9/20 0.59
GRIK1 P39086 3/20 0.49
ACLY P53396 1/20 0.47
CDC7 O00311 1/20 0.46
DAPK3 O43293 1/20 0.46
PAK4 O96013 1/20 0.46
PIM1 P11309 1/20 0.46
CDK2 P24941 1/20 0.46
FLT3 P36888 1/20 0.46
GSK3B P49841 1/20 0.46
CDK9 P50750 1/20 0.46
CDK5 Q00535 1/20 0.46
DYRK1A Q13627 1/20 0.46
MELK Q14680 1/20 0.46
MINK1 Q8N4C8 1/20 0.46
HIPK2 Q9H2X6 1/20 0.46
STK17A Q9UEE5 1/20 0.46
MPO P05164 1/20 0.46
DHODH Q02127 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10171027 0.90 AKR1C3 (0.70) AKR1C3AKR1C2GRIK1ACLYMPO
SCHEMBL9709047 0.85 AKR1C3 (0.60) AKR1C3AKR1C2GRIK1ACLYMPO
SCHEMBL4215379 0.84 AKR1C3 (0.52) AKR1C3AKR1C2MAPT
SCHEMBL1415570 0.83 MAPT (0.56) AKR1C3AKR1C2GRIK1CDC7DAPK3
SCHEMBL4226484 0.83 XDH (0.54) AKR1C3AKR1C2GRIK1ACLYCDC7
SCHEMBL14392041 0.83 AKR1C3 (0.51) AKR1C3AKR1C2GRIK1CDC7DAPK3
SCHEMBL14392056 0.81 AKR1C3 (0.50) AKR1C3AKR1C2GRIK1CDC7DAPK3
SCHEMBL14392471 0.81 MAP2K1 (0.51) AKR1C3AKR1C2GRIK1CDC7DAPK3
SCHEMBL4213857 0.81 AKR1C3 (0.56) AKR1C3AKR1C2GRIK1CDC7DAPK3
SCHEMBL13890924 0.81 AKR1C3 (0.50) AKR1C3AKR1C2GRIK1CDC7DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 AKR1C3 105/4885AKR1C2 287/4885GRIK1 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.